感染 COVID-19 的非小细胞肺癌 (NSCLC) 患者的预后要差得多。然而，这种现象背后的具体机制仍不清楚。我们进行了一项多中心研究，收集了三个中心总共 36 名 NSCLC 患者的手术组织样本进行分析。 36名肺癌患者中，有9人感染了COVID-19。 COVID-19感染（HR = 21.62 [1.58, 296.06]，p = 0.021）是无进展生存期（PFS）的独立危险因素。对这些癌症组织的 RNA-seq 数据分析表明，感染 COVID-19 的肺癌患者铜凋亡相关基因的表达水平显着升高。使用 Lasso 回归和 Cox 回归分析，我们鉴定了 12 个调节铜凋亡的长非编码 RNA (lncRNA)。基于这些 lncRNA 的评分用于将患者分为高风险组和低风险组。结果显示，与低风险组相比，高风险组的总生存率和 PFS 较低。此外，肿瘤免疫功能障碍和排除（TIDE）数据库显示，高危人群从免疫治疗中受益更多。药物敏感性分析确定西妥昔单抗和吉非替尼是高危人群的潜在有效治疗方法。铜中毒在感染了 COVID-19 的 NSCLC 患者中发挥着重要作用。令人鼓舞的是，西妥昔单抗和吉非替尼已显示出治疗这些患者的潜在有效性。© 2024 作者。细胞与分子医学基金会和约翰·威利出版的《细胞与分子医学杂志》

Non-small cell lung cancer (NSCLC) patients infected with COVID-19 experience much worse prognosis. However, the specific mechanisms behind this phenomenon remain unclear. We conducted a multicentre study, collecting surgical tissue samples from a total of 36 NSCLC patients across three centres to analyse. Among the 36 lung cancer patients, 9 were infected with COVID-19. COVID-19 infection (HR = 21.62 [1.58, 296.06], p = 0.021) was an independent risk factor of progression-free survival (PFS). Analysis of RNA-seq data of these cancer tissues demonstrated significantly higher expression levels of cuproptosis-associated genes in COVID-19-infected lung cancer patients. Using Lasso regression and Cox regression analysis, we identified 12 long noncoding RNAs (lncRNA) regulating cuproptosis. A score based on these lncRNA were used to divide patients into high-risk and low-risk groups. The results showed that the high-risk group had lower overall survival and PFS compared to the low-risk group. Furthermore, Tumor Immune Dysfunction and Exclusion (TIDE) database revealed that the high-risk group benefited more from immunotherapy. Drug sensitivity analysis identified cetuximab and gefitinib as potentially effective treatments for the high-risk group. Cuproptosis plays a significant role NSCLC patients infected with COVID-19. Promisingly, cetuximab and gefitinib have shown potential effectiveness for managing these patients.© 2024 The Author(s). Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.